Other Non-Current Assets - Narrative (Details) $ in Thousands	3 Months Ended	12 Months Ended
	Jun. 30, 2020 USD ($)	Dec. 31, 2024 USD ($) payment royalty_payment	Dec. 31, 2023 USD ($) payment
Accounts, Notes, Loans and Financing Receivable [Line Items]
Revenues		$ 57,561	$ 50,583
Number of guaranteed royalty payments | royalty_payment		8
License Agreement with Sunovion Pharmaceuticals, Inc.
Accounts, Notes, Loans and Financing Receivable [Line Items]
Minimum royalty receivable	$ 1,000	$ 1
Number of annual royalty payments receivable | payment		4	5
Mitsubishi Tanabe Pharma America, Inc And Haisco For Exarvan
Accounts, Notes, Loans and Financing Receivable [Line Items]
Sales commissions and fees		$ 191
Royalty
Accounts, Notes, Loans and Financing Receivable [Line Items]
Revenues		$ 1,008	$ 989
Royalty | License Agreement with Sunovion Pharmaceuticals, Inc.
Accounts, Notes, Loans and Financing Receivable [Line Items]
Revenues	$ 8,000